Clinical Scorecard: Neoadjuvant Chemotherapy Strategies and a Decade of Survival Outcomes in Advanced Ovarian Cancer
At a Glance
Category
Detail
Condition
Stage IIIC or IV epithelial ovarian cancer
Study Design
Retrospective cohort study using the National Cancer Database to assess treatment patterns and survival outcomes from 2004 through 2015
Treatments Compared
Neoadjuvant chemotherapy (NACT) followed by interval surgery versus primary debulking surgery (PDS)
Study Population
Patients diagnosed with stage IIIC or IV epithelial ovarian cancer from January 1, 2004, through December 31, 2015
Key Findings
NACT was associated with similar overall and progression-free survival compared with PDS; greater NACT use was associated with lower early mortality but not with long-term survival probability
Key Highlights
NACT shows similar overall survival and progression-free survival compared to PDS.
Higher NACT utilization is associated with lower early mortality.
No association found between NACT adoption and long-term survival probability.
Guideline-Based Recommendations
Diagnosis
Diagnosis of advanced-stage epithelial ovarian cancer should be confirmed through imaging and histopathology.
Management
Consider PDS when complete or optimal cytoreduction is feasible.
Monitoring & Follow-up
Monitor for perioperative morbidity and long-term survival outcomes.
Risks
Preoperative chemotherapy may select for resistant clones, potentially impairing long-term outcomes.
Patient & Prescribing Data
Patients diagnosed with stage IIIC or IV epithelial ovarian cancer from January 1, 2004, through December 31, 2015.
NACT use increased among high-use programs, with no compromise in median overall survival.
Clinical Best Practices
Utilize comparative effectiveness research methods to evaluate treatment outcomes.
Adhere to national guidelines favoring PDS when feasible.
by Alex E. R. Powers, Gretchen Davis, Deshae Jenkins, Alicia Youssef, William Manning, Jason D. Wright, Nancy L. Keating, Amy Bregar, Alejandro Rauh-Hain, Alexander Melamed